About Forty Seven
Forty Seven is a company based in Palo Alto (United States) founded in 2015 was acquired by Gilead in March 2020.. Forty Seven has raised $150 million across 4 funding rounds from investors including Gilead, Blackstone and Lightspeed Venture Partners. Forty Seven offers products and services including Trodelvy and HIV Medicines. Forty Seven operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Palo Alto, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Forty Seven
Forty Seven offers a comprehensive portfolio of products and services, including Trodelvy and HIV Medicines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for certain metastatic breast cancers
Medications for HIV and viral hepatitis management
Unlock access to complete
Unlock access to complete
Leadership Team
294 people
Software Development Team
183 people
Senior Team
62 people
Legal and Compliance
41 people
Data Analysis and Operations Team
38 people
Human Resources and Administration
38 people
Operations Team
38 people
Finance and Accounting
36 people
Unlock access to complete
Funding Insights of Forty Seven
Forty Seven has successfully raised a total of $150M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $6.0M
-
First Round
First Round
(24 Feb 2016)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2019 | Amount | Post-IPO - Forty Seven | Valuation |
investors |
|
| Dec, 2017 | Amount | Grant - Forty Seven | Valuation |
investors |
|
| Oct, 2017 | Amount | Series B - Forty Seven | Valuation | Wellington |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Forty Seven
Forty Seven has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Gilead, Blackstone and Lightspeed Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners.
|
Founded Year | Domain | Location | |
|
VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Forty Seven
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Forty Seven
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Forty Seven Comparisons
Competitors of Forty Seven
Forty Seven operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Forty Seven
Frequently Asked Questions about Forty Seven
When was Forty Seven founded?
Forty Seven was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Forty Seven located?
Forty Seven is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Is Forty Seven a funded company?
Forty Seven is a funded company, having raised a total of $150M across 4 funding rounds to date. The company's 1st funding round was a Series B of $75M, raised on Feb 24, 2016.
What does Forty Seven do?
Forty Seven was founded in 2015 in Palo Alto, United States, within the biotechnology sector. Therapies targeting a range of diseases are developed, with a focus on oncology, viral, and inflammatory conditions. The lead candidate, Hu5F9-G4, is a monoclonal antibody directed at the CD47 receptor, which is upregulated on many tumor cells to inhibit macrophage phagocytosis. Operations center on advancing these immunomodulatory treatments through preclinical and clinical stages.
Who are the top competitors of Forty Seven?
Forty Seven's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Forty Seven offer?
Forty Seven offers Trodelvy and HIV Medicines.
Who are Forty Seven's investors?
Forty Seven has 9 investors. Key investors include Gilead, Blackstone, Lightspeed Venture Partners, Leukemia & Lymphoma Society, and CIRM.